91 related articles for article (PubMed ID: 10658293)
1. The ATLAS study: low-dose versus high-dose lisinopril in heart failure.
Horowitz JD
Int J Clin Pract Suppl; 1999 Apr; 100():15-6. PubMed ID: 10658293
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial.
Rydén L; Armstrong PW; Cleland JG; Horowitz JD; Massie BM; Packer M; Poole-Wilson PA
Eur Heart J; 2000 Dec; 21(23):1967-78. PubMed ID: 11071803
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Treatment with Lisinopril and Survival ATLAS study.
Int J Clin Pract Suppl; 1999 Apr; 100():24. PubMed ID: 10658297
[No Abstract] [Full Text] [Related]
4. Results of the ATLAS study.
Rydén L
Int J Clin Pract Suppl; 1999 Apr; 100():17-8. PubMed ID: 10658294
[No Abstract] [Full Text] [Related]
5. Implications of the ATLAS study for clinical practice.
Packer M
Int J Clin Pract Suppl; 1999 Apr; 100():21-3. PubMed ID: 10658296
[No Abstract] [Full Text] [Related]
6. Heart failure management in primary care: implications of the ATLAS study.
Int J Clin Pract Suppl; 1999 Apr; 100():25-30. PubMed ID: 10658298
[No Abstract] [Full Text] [Related]
7. ATLAS: high dose lisinopril is superior to low dose in heart failure.
Jackson G
Int J Clin Pract; 1998; 52(3):139. PubMed ID: 9684425
[No Abstract] [Full Text] [Related]
8. What does ATLAS really tell us about "high" dose angiotensin-converting enzyme inhibition in heart failure?
Nicklas JM; Cohn JN; Pitt B
J Card Fail; 2000 Jun; 6(2):165-8. PubMed ID: 10908091
[TBL] [Abstract][Full Text] [Related]
9. Causes of death in the ATLAS study: effects of high-dose ACE inhibitors.
Cleland JG
Int J Clin Pract Suppl; 1999 Apr; 100():19-20. PubMed ID: 10658295
[No Abstract] [Full Text] [Related]
10. Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study.
Cleland JG; Armstrong P; Horowitz JD; Massie B; Packer M; Poole-Wilson PA; Rydén L
Eur J Heart Fail; 1999 Mar; 1(1):73-9. PubMed ID: 10937983
[TBL] [Abstract][Full Text] [Related]
11. Is more better? About dose levels of ACE inhibitors in chronic heart failure.
Swedberg K
Eur Heart J; 2000 Dec; 21(23):1902-3. PubMed ID: 11071789
[No Abstract] [Full Text] [Related]
12. Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study.
Cleland JG; Thygesen K; Uretsky BF; Armstrong P; Horowitz JD; Massie B; Packer M; Poole-Wilson PA; Rydén L;
Eur Heart J; 2001 Sep; 22(17):1601-12. PubMed ID: 11492990
[TBL] [Abstract][Full Text] [Related]
13. [Val-HeFT-Valsartan Heart Failure Trial].
Haghfelt T
Ugeskr Laeger; 2001 Mar; 163(13):1867. PubMed ID: 11293319
[No Abstract] [Full Text] [Related]
14. Role and optimal dosing of angiotensin-converting enzyme inhibitors in heart failure.
Kazi D; Deswal A
Cardiol Clin; 2008 Feb; 26(1):1-14, v. PubMed ID: 18312901
[TBL] [Abstract][Full Text] [Related]
15. Comparison of angiotensin-converting enzyme inhibitors in the treatment of congestive heart failure.
Tu K; Mamdani M; Kopp A; Lee D
Am J Cardiol; 2005 Jan; 95(2):283-6. PubMed ID: 15642572
[TBL] [Abstract][Full Text] [Related]
16. Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group.
Sculpher MJ; Poole L; Cleland J; Drummond M; Armstrong PW; Horowitz JD; Massie BM; Poole-Wilson PA; Ryden L
Eur J Heart Fail; 2000 Dec; 2(4):447-54. PubMed ID: 11113723
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure.
Chen YT; Wang Y; Radford MJ; Krumholz HM
Am Heart J; 2001 Mar; 141(3):410-7. PubMed ID: 11231438
[TBL] [Abstract][Full Text] [Related]
18. High-versus low-dose ACE inhibitor therapy in chronic heart failure.
Roffman DS
Ann Pharmacother; 2004 May; 38(5):831-8. PubMed ID: 15026561
[TBL] [Abstract][Full Text] [Related]
19. ATLAS shows global undertreatment of heart failure.
Husten L
Lancet; 1998 Apr; 351(9108):1035. PubMed ID: 9546519
[No Abstract] [Full Text] [Related]
20. High- vs low-dose ACE inhibition in chronic heart failure.
Hosp Med; 1999 Mar; 60(3):220. PubMed ID: 10476251
[No Abstract] [Full Text] [Related]
[Next] [New Search]
